The study, called
the Bypass Surgery Versus Everolimus - Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST) trial, is one of only two randomized controlled trials to compare bypass to angioplasty since the introduction of everolimus - eluting stents, a new generation of drug - eluting stent.
Bypass surgery showed a clear advantage only in the percentages of patients who had to return to have an artery reopened: 3.1 percent for the bypass group, versus 7.2 percent per year for the stent
Bypass surgery showed a clear advantage only in the percentages of patients who had to return to have an artery reopened: 3.1 percent for the
bypass group, versus 7.2 percent per year for the stent
bypass group,
versus 7.2 percent per year for the stent group.